Validation Data Gallery
|Sample-dependent, check data in validation data gallery|
11145-1-AP targets Glypican 3 in WB, ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Glypican 3 fusion protein Ag1433|
|Full Name||glypican 3|
|Calculated molecular weight||580 aa, 66 kDa|
|Observed molecular weight||66 kDa|
|GenBank accession number||BC035972|
|Gene ID (NCBI)||2719|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.1% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Glypicans (GPCs) are a family of glycosylphosphatidylinositol (GPI)-anchored heparan sulphate proteoglycans (HSPGs) that may play a role in the control of cell division and growth regulation. In mammals, there are six GPCs (GPC1 to GPC6), all of which have a similar core-protein size of approx. 60 kDa and the clustering of glycosaminoglycan attachment site near the C-terminus. They are tethered to the cell surface by GPI linkages, which can be cleaved by endogenous phospholipases, thus releasing the protein. Glypican 3 (GPC3) is highly expressed in many tissues during development and plays an important role in the regulation of embryonic growth (PMID: 22467855). Loss-of-function mutations of GPC3 result in the Simpson-Golabi-Behmel overgrowth syndrome (SGBS), and Gpc-3 null mice display developmental overgrowth (PMID: 8589713; 18477453). In hepatocellular carcinoma (HCC), the overexpression of GPC3 has been demonstrated to be a reliable diagnostic indicator (PMID: 19212669; 22706665).
Mol Med Rep
Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells.
Cell Physiol Biochem
N-Cadherin Maintains the Healthy Biology of Nucleus Pulposus Cells under High-Magnitude Compression.
Aging (Albany NY)
Kinsenoside ameliorates intervertebral disc degeneration through the activation of AKT-ERK1/2-Nrf2 signaling pathway.